Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 897-906

  Guix, Marta ^a   Granja, Nara De Matos ^a   Meszoely, Ingrid ^a   Adkins, Theresa B ^a   Wieman, Bobbye M ^a   Frierson, Kerek E ^a   Sanchez, Violeta ^a   Sanders, Melinda E ^a   Grau, Ana M ^a   Mayer, Ingrid A ^a   Pestano, Gary ^a   Shyr, Yu ^a   Muthuswamy, Senthil ^a   Calvo, Benjamin ^a   Krontiras, Helen ^a   Krop, Ian E ^a   Kelley, Mark C ^a   Arteaga, Carlos L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ESTROGEN RECEPTOR ALPHA; HORMONE RECEPTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG INHIBITION; FEMALE; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOUSE; MUCOSA INFLAMMATION; NAUSEA; NICK END LABELING; NONHUMAN; ORAL MUCOSAL DISEASE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASH; RAT; SHORT COURSE THERAPY; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TUMOR CELL; VOMITING; XENOGRAFT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MICE; MICE, NUDE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 39749085432     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.5939     Document Type: Article

References (34)

1. Dowsett M, Dixon JM, Horgan K, et al: Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res 6:2260-2267, 2000
2. Dowsett M, Bundred NJ, Decensi A, et al: Effect of raloxifene on breast cancer cell Ki67 and apoptosis: A double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 10:961-966, 2001
3. DeFriend DJ, Howell A, Nicholson RI, et al: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408-414, 1994
4. Assersohn L, Salter J, Powles TJ, et al: Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82:113-123, 2003
5. Mohsin SK, Weiss HL, Gutierrez MC, et al: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468, 2005
6. Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer: A study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005
7. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
8. Zhao M, He P, Rudek MA, et al: Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793:413-420, 2003
9. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999
10. Perez-Torres M, Guix M, Gonzalez A, et al: Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem 281:40183-40192, 2006
11. Koizumi F, Shimoyama T, Taguchi F, et al: Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116:36-44, 2005
12. Wang SE, Shin I, Wu FY, et al: HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res 66:9591-9600, 2006
13. Yauch RL, Januario T, Eberhard DA, et al: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686-8698, 2005
14. Muthuswamy SK, Gilman M, Brugge JS: Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19:6845-6857, 1999
15. Arteaga CL, Hurd SD, Dugger TC, et al: Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein. Cancer Res 54:4703-4709, 1994
16. Bjornstrom L, Sjoberg M: Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833-842, 2005
17. Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112, 2002
18. Sarwar N, Kim JS, Jiang J, et al: Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 13:851-861, 2006
19. Ellis MJ, Tao Y, Bhatnagar AS, et al: Cell cycle complete response after neoadjuvant letrozole predicts superior relapse-free and overall survival: Long-term follow-up of the letrozole P024 study. J Clin Oncol 25:20s, 2007 (suppl 18S; abstr 570)
20. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
21. Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323-5333, 2005
22. Winer EP, Cobleigh M, Dickler M, et al: Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI- 774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 76:445A, 2002 (abstr)
23. Agrawal A, Gutteridge E, Cheung KL, et al: Efficacy and tolerability of gefitinib in oestrogen receptor negative and tamoxifen resistant oestrogen receptor positive locally advanced or metastatic breast cancer. Breast Cancer Res Treat 24:S61, 2005 (suppl)
24. Polychronis A, Sinnett HD, Hadjiminas D, et al: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383-391, 2005
25. Ciardiello F, Troiani T, Caputo F, et al: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 94:1604-1609, 2006
26. Tan AR, Yang X, Hewitt SM, et al: Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22:3080-3090, 2004
27. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
28. Lu JF, Eppler SM, Wolf J, et al: Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80:136-145, 2006
29. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005
30. Moulder SL, Yakes FM, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
32. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
33. Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441, 2007
34. Livasy CA, Perou CM, Karaca G, et al: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38:197-204, 2007